Southwest Securities released a research report on April 8 stating that Tiger Pharmaceuticals (300347.SZ) was given a purchase rating. The main reasons for the rating include: 1) short-term profits were slightly disrupted, and the main business still showed strong resilience; 2) overseas business continued to expand, and integrated service capabilities continued to increase; 3) steady growth in on-hand orders showed a recovery trend. (Mainichi Keizai Shimbun)
西南证券4月8日发布研报称，给予泰格医药（300347.SZ）买入评级。评级理由主要包括：1）短期利润略有扰动，主营业务仍表现较强韧性；2）海外业务不断延伸，一体化服务能力持续增强；3）在手订单稳健增长呈现恢复趋势。（每日经济新闻）
Southwest Securities released a research report on April 8 stating that Tiger Pharmaceuticals (300347.SZ) was given a purchase rating. The main reasons for the rating include: 1) short-term profits were slightly disrupted, and the main business still show
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.